Coya Therapeutics, Inc. (COYA)
NASDAQ: COYA · Real-Time Price · USD
4.147
+0.197 (4.98%)
Oct 27, 2026, 2:50 PM EDT - Market open
Coya Therapeutics Revenue
Coya Therapeutics had revenue of $243.75K in the quarter ending June 30, 2026, with 48.97% growth. This brings the company's total for the last twelve months to $8.02M, up 1,793.76% year-over-year. In the year 2025, Coya Therapeutics had annual revenue of $7.95M with 123.57% growth. That makes Coya Therapeutics the 38,282nd largest company in the world by revenue and 5,031st in the United States.
Revenue (ttm)
$8.02M
Revenue Growth
+1,793.76%
P/S Ratio
11.55
Revenue / Employee
$1,002,393
Employees
8
Market Cap
97.27M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.95M | 4.39M | 123.57% |
| Dec 31, 2024 | 3.55M | -2.45M | -40.79% |
| Dec 31, 2023 | 6.00M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| ImmuCell | 30.68M |
| Tonix Pharmaceuticals Holding | 29.10M |
| NeurAxis | 5.32M |
| Milestone Pharmaceuticals | 2.34M |
| Rallybio | 646.00K |
| Inovio Pharmaceuticals | 65.34K |
| Genelux | 8.00K |
COYA News
- 13 days ago - Coya Therapeutics to initiate OLE of Phase 2/3 ALSTARS trial of COYA 302 - TheFly
- 13 days ago - Coya to Initiate Open-Label Extension of Phase 2/3 ALSTARS Trial of COYA 302 in ALS - Business Wire
- 13 days ago - Coya Therapeutics Slides: Investor presentation - Filings
- 14 days ago - Coya Therapeutics Announces Participation at Chardan's 10th Annual Healthcare Conference - Business Wire
- 22 days ago - Coya announces full enrollment in Phase 2/3 ALSTARs trial of COYA 302 - TheFly
- 22 days ago - Coya Therapeutics Announces Completion of Full Enrollment in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS - Business Wire
- 6 weeks ago - Coya Therapeutics announces 100th patient enrolled in Phase 2/3 ALSTARS trial - TheFly
- 6 weeks ago - Coya Therapeutics Announces Enrollment of 100th Participant in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS - Business Wire